Research progress of sotagliflozin in treatment of cardiovascular complications of patients with type 2 diabetes mellitus
The incidence of type 2 diabetes mellitus(T2DM)is increasing,and its development can result in several complications,including cardiac,renal,vascular,and neurological problems.Cardiovascular complications are the leading cause of death in patients with T2DM.Sotagliflozin,a dual SGLT inhibitor,may reduce cardiovascular complications,and improve cardiac outcome and patients'survival rate.
Type 2 diabetes mellitusCardiovascular complicationsSotagliflozinProgress
万方数据
维普
